Cases of breast cancer have also been reported in younger women and the leading cause in them is their lifestyle pattern or they may be carriers of high penetrance mutated genes.Classification, diagnosis, and prediction of the outcomes have been made through tissue and serum biomarkers but these also fail to diagnose the disease at an early stage. Considerably there is no adequate detection technique present globally that can help early detection and provide adequate specificity, safety, sensitivity, and convenience for the younger and premenopausal women, thereby it becomes necessary to take early measures and build efficient tools and techniques for the same. Through biopsies of nipple aspirate fluid (NAF) biomarker profiling can be performed. NAF can help display a paradigm shift in the management of breast cancer which can help women patients to self-analyze breast cancer development.
The Correction to this article has been published in Clinical Proteomics 2024 21:20
2025
Glycoproteomics: Technologies and Clinical Applications
High Resolution Spatial Proteomics at Single-Cell Levels
2024
Extracellular Vesicles and Proteomics
Liquid biopsy applications of proteomics
2023
Bioinformatic approaches for clinical proteomics: too many choices and no standardization
Clinical translation of targeted proteomics
In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Glycoproteomics: Technologies and Clinical Applications
Guest edited by Hui Zhang and Naoyuki Taniguchi
Read more
High Resolution Spatial Proteomics at Single-Cell Levels
Guest edited by Hui Zhang and Tiannan Guo
Read more
Extracellular Vesicles and Proteomics
Guest edited by Fabrice Lucien-Matteoni
Read more
Liquid biopsy applications of proteomics
Guest edited by Samir Hanash, Stephen Pennington, Jochen Schwenk
Read more
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Trezvuy - Fotolia
Make a suggestion here
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 3.9
Source Normalized Impact per Paper (SNIP): 0.831
SCImago Journal Rank (SJR): 1.015
Speed 2024
Submission to first editorial decision (median days): 10
Submission to acceptance (median days): 126
Usage 2024
Downloads: 401,225
Altmetric mentions: 182
Clinical Proteomics